Actinium Pharmaceuticals will showcase Phase 1 clinical results for ATNM-400 at EANM 2026, targeting advancements in prostate and lung cancer treatments beyond traditional PSMA approaches.
Actinium Pharmaceuticals is set to showcase clinical progress for its ATNM-400 program at the upcoming EANM 2026 conference. The presentation will highlight first-in-human Phase 1 data for metastatic castration-resistant prostate cancer and preclinical findings for KRAS- and ALK-driven non-small cell lung cancer, demonstrating the asset's potential to address therapeutic gaps beyond standard PSMA approaches.
The data focuses on metastatic castration-resistant prostate cancer, specifically exploring a differentiated approach that goes beyond traditional PSMA targeting.
Yes, the company is also evaluating ATNM-400 in preclinical studies for non-small cell lung cancer, specifically targeting KRAS- and ALK-driven mutations.
Actinium Pharmaceuticals announced plans to unveil first-in-human Phase 1 clinical data for its ATNM-400 candidate at the upcoming EANM 2026 conference. The presentation will highlight the drug's efficacy in treating metastatic castration-resistant prostate cancer and its potential application in KRAS- and ALK-driven non-small cell lung cancer.
The presentation will feature first-in-human Phase 1 data for ATNM-400 in treating metastatic castration-resistant prostate cancer, alongside preclinical studies for lung cancer.